BTK and B-cell chronic lymphocytic leukemia: In addition, several non-C481 mutations have been observed in patients resistant to irreversible BTKi (19, 21) and, more recently, in relapsed chronic lymphocytic leukemia patients treated with the noncovalent BTK inhibitor pirtobrutinib (22).